Enrofloxacin structure
|
Common Name | Enrofloxacin | ||
---|---|---|---|---|
CAS Number | 93106-60-6 | Molecular Weight | 359.395 | |
Density | 1.4±0.1 g/cm3 | Boiling Point | 560.5±50.0 °C at 760 mmHg | |
Molecular Formula | C19H22FN3O3 | Melting Point | 225 °C | |
MSDS | Chinese USA | Flash Point | 292.8±30.1 °C |
Use of EnrofloxacinEnrofloxacin is an effective antibiotic with an MIC90 of 0.312 μg/mL for Mycoplasma bovis. |
Name | enrofloxacin |
---|---|
Synonym | More Synonyms |
Description | Enrofloxacin is an effective antibiotic with an MIC90 of 0.312 μg/mL for Mycoplasma bovis. |
---|---|
Related Catalog | |
Target |
MIC90: 0.312 μg/mL ( Mycoplasma bovis)[1] |
In Vitro | Mycoplasma bovis is a worldwide pathogen, causative agent of pneumonia, mastitis, arthritis, and a variety of other symptoms in cattle. The antibiotic susceptibility profiles of the Hungarian strains are consistent within the tested group of fluoroquinolones. Three isolates (MYC44, MYC45 and MYC46) have high MIC values (≥10 μg/mL) to Enrofloxacin, while the rest of the strains are inhibited by Enrofloxacin with MICs ≤0.312 or 0.625 μg/mL[1]. |
In Vivo | Mice (n=80) undergo transient middle cerebral artery occlusion (MCAo) with reperfusion after 60 minutes. After MCAo, animals are randomly assigned to receive either a daily preventive medication (n=26, Enrofloxacin) starting at the day of MCAo or a therapeutic medication (n=25; Enrofloxacin) after diagnosis of lung infection. Standard treatment started immediately after the appearance of clinical signs (general health score>6) usually between day 4 and 6 after stroke. Both, preventive and standard antibiotic treatment using Enrofloxacin improve survival in a similar way compared with placebo treatment[2]. |
Animal Admin | Mice[2] 11- to 14-week-old C57Bl6/J male mice are used. Enrofloxacin (2.5% oral solution) is dispensed in saline (2 mg/mL), antibiotic-treated animals receive a daily orally dispensed dose of 10 mg/kg body weight via feeding needle every 12 hours over a period of 7 days, while placebo animals receive the same amount of saline via feeding needle. Animals of preventive antibiotic group obtained Enrofloxacin after waking from reperfusion anesthesia (ca. 1 hour after operation). Therapeutic antibiotic treatment is given immediately after appearance of clinical signs (general health score>5) and confirmation of lung infection by MRI (signal rate≥5%). The group allocation is randomized[2]. |
References |
Density | 1.4±0.1 g/cm3 |
---|---|
Boiling Point | 560.5±50.0 °C at 760 mmHg |
Melting Point | 225 °C |
Molecular Formula | C19H22FN3O3 |
Molecular Weight | 359.395 |
Flash Point | 292.8±30.1 °C |
Exact Mass | 359.164520 |
PSA | 65.78000 |
LogP | 1.88 |
Vapour Pressure | 0.0±1.6 mmHg at 25°C |
Index of Refraction | 1.634 |
Storage condition | -20°C Freezer |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
MUTATION DATA
|
Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
---|---|
Hazard Codes | Xi: Irritant; |
Risk Phrases | R36/37/38 |
Safety Phrases | 26-36/37 |
RIDADR | NONH for all modes of transport |
WGK Germany | 3 |
RTECS | VB1993650 |
Precursor 10 | |
---|---|
DownStream 1 | |
Experimental study of the impact of antimicrobial treatments on Campylobacter, Enterococcus and PCR-capillary electrophoresis single-strand conformation polymorphism profiles of the gut microbiota of chickens.
J. Med. Microbiol. 63(Pt 11) , 1552-60, (2014) An experiment was conducted to compare the impact of antimicrobial treatments on the susceptibility of Campylobacter, Enterococcus faecium and Enterococcus faecalis, and on the diversity of broiler mi... |
|
Ultrastructural changes associated with dexamethasone-induced ocular hypertension in mice.
Invest. Ophthalmol. Vis. Sci. 55(8) , 4922-33, (2014) To determine whether dexamethasone (DEX)-induced ocular hypertension (OHT) in mice mimics the hallmarks of steroid-induced glaucoma (SIG) in humans, including reduced conventional outflow facility (C)... |
|
New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.
Antimicrob. Agents Chemother. 51 , 3354-60, (2007) Plasmid-mediated Qnr and AAC(6')-Ib-cr have been recognized as new molecular mechanisms affecting fluoroquinolone (FQ) resistance. C316, an Escherichia coli strain demonstrating resistance to various ... |
bayvp2674 |
Enorfloxacin |
Enrolfoxacin |
1-cyclopropyl-7-(4-ethyl-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid |
cfpq |
Enrofoxacin |
Enrofloxacin |
1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-ethyl-1-piperazinyl)-quinoline-3-carboxylic acid |
1-cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid |
ROFLOXACIN BASE |
MFCD01861684 |
Baytri |
1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-ethyl-1-piperazinyl)-3-quinolinecarboxylic acid |
1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-ethylpiperazino)-quinoline-3-carboxylic acid |